Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

Status:

Recruiting

Phase

2nd+

Line of Therapy

Any Stage

Disease Stage

Biomarker(s)

MET, WEE1

Investigational

Product

Mixed

Treatment Arms

o WEE-1 inhibitor

o cMET inhibitor

o novel non-steroidal androgen receptor (AR) antagonist

o CFI400945 PLK4 inhibitor

o Ipatasertib AKT inhibitor

o Durvalumab and Tremelimumab immunotherapy

o Carboplatin platinum based chemotherapy